News

Deal Announcements

Bristol-Meyers Squibb To Acquire Adnexus Therapeutics

Tuesday, September 25, 2007 5:00:00 AM PDT | VentureDeal Staff
WALTHAM, MA -- Pharmaceutical company Bristol-Meyers Squibb (NYSE: BMY) announced that it has entered into a definitive agreement to acquire Adnexus Therapeutics, Inc. for approximately $490 million, including potential future performance payouts.

Adnexus is a biotechnology company that is developing what it considers is a breakthrough class of protein therapeutics that it calls AdNectins. 

The company was scheduled to go public via an IPO, and will not do so assuming the transaction closes.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1